The purpose of the current study was to determine quality of life and tumor control from a prospective phase 2 clinical trial evaluating deintensified chemoradiotherapy for favorable risk, human papillomavirus (HPV)-associated oropharyngeal squamous cell carcinoma. METHODS: Patients with T0-T3, N0-N2c, M0, p16-positive disease and a minimal smoking history were treated with 60 grays of intensity-modulated radiotherapy with concurrent weekly intravenous cisplatin (30 mg/m 2 ). The primary study endpoint was the pathologic complete response rate based on biopsy of the primary site and dissection of pretreatment positive lymph node regions. The pathologic complete response rate as previously reported was 86%. Herein, the authors report secondary endpoint measures of local control, regional control, cause-specific survival, distant metastasis-free survival, and overall survival, and patient- . RESULTS: A total of 44 patients enrolled with a median follow-up of 36 months (88% with 2 years). The 3-year local control, regional control, cause-specific survival, distant metastasis-free survival, and overall survival rates were 100%, 100%, 100%, 100%, and 95%, respectively. The mean before and 3-year after EORTC QOL scores were: global: 80 of 78; swallowing: 11 of 11; dry mouth: 16 of 41; and sticky saliva: 6 of 29. The mean before and 3-year after PRO-CTCAE scores were: swallowing: 0.4 of 0.7; and dry mouth: 0.4 of 1.4. Approximately 39% of patients required a feeding tube (median duration, 15 weeks; none were permanent). There were no grade 3 late adverse events reported. CONCLUSIONS: For patients with favorable-risk human papillomavirus-associated oropharyngeal squamous cell carcinoma, a substantially decreased intensity of therapy with 60 grays of intensity-modulated radiotherapy and weekly low-dose cisplatin produced better preservation of quality of life compared with standard therapies while maintaining excellent 3-year tumor control and survival.
INTRODUCTION
Cancer control and survival appears to be excellent in patients with human papillomavirus-associated oropharyngeal squamous cell carcinoma (OPSCC), 1 but standard chemoradiotherapy (CRT) regimens produce substantial toxicity. 2 The major effort now is to evaluate less intensive (ie, deintensified) treatment regimens with the goals of maintaining excellent cancer control and decreasing toxicity. There are several different approaches that currently are being studied, with varying degrees of actual deintensification. [3] [4] [5] [6] [7] [8] [9] The most common approaches have decreased the radiation dose by either: 1) increasing the chemotherapy dose (ie, the addition of neoadjuvant chemotherapy); or 2) adding primary treatment with transoral surgery. 4, 8, 10 The limitation of these approaches is that there is little change in the overall intensity of the therapy because they increase the intensity of chemotherapy or surgery to decrease the radiation dose.
In 2011, we initiated a program of deintensification with a substantial reduction in the radiation and chemotherapy dose without adding neoadjuvant chemotherapy or definitive surgery. Our deintensified CRT regimen consists of 60 gray (Gy) (2 Gy/fraction, daily) of intensity-modulated radiotherapy (IMRT) with concurrent weekly cisplatin at a dose of 30 mg/m 2 (cumulative dose of 180 mg/m 2 ). 9 When we started our study, the concept of deintensification was so new that we designed our protocol with a pathologic endpoint so that we would know as quickly as possible if tumor control was being compromised. Because the initial report of our experience in 2015 9, 11 was so favorable, we opened a second version of our protocol that decreased treatment intensity further (ClinicalTrials.gov identifier: NCT02281955). The NRG Oncology cooperative group has also recently completed enrollment for a phase 2 randomized trial that also is revaluating a 60-Gy radiation dose reduction. 12 The future of these deintensification efforts assumes that our initial results will be maintained with longer follow-up. The purpose of this article was to provide this information by reporting the mature results of our initial deintensification protocol with emphasis on long-term tumor control and patient-reported outcomes.
MATERIALS AND METHODS

Study Design and Eligibility
This phase 2 study was registered with the National Cancer Institute (www.clinicaltrials.gov identifier NCT01530997) and approved by the institutional review boards at the participating centers. All patients provided written informed consent. Enrolling institutions included the University of North Carolina Hospitals (Chapel Hill, North Carolina), University of Florida Hospitals (Gainesville, Florida), and Rex Hospital (Raleigh, North Carolina).
Eligible patients had untreated pathologically confirmed human papillomavirus (HPV)-associated or p16-positive OPSCC or from an unknown head and neck primary site; were aged 18 years; had T0 to T3, N0 to N2c, M0 disease (American Joint Committee on Cancer [AJCC] seventh edition; T0 to T3 N1 to N2 as per AJCC eighth edition) disease; a smoking history of 10 packyears or >10 pack-years and abstinent for the past 5 years; Eastern Cooperative Oncology Group performance status of 0 to 1; adequate hematological, renal, and liver function; and no history of prior head and neck cancers. HPV and p16 were analyzed as per institutional standards by florescence in situ hybridization or immunohistochemistry. p16 positivity was defined as >70% of carcinoma cells showing nuclear reactivity.
Study Treatment
All patients had standard-of-care pretreatment evaluations and staging procedures including: 1) complete history and physical examination (including fiberoptic nasolaryngopharyngoscopy); 2) panendoscopy with directed biopsies and tonsillectomies if the primary tumor was unknown; 3) diagnostic contrasted neck computed tomography (CT) and chest CT (positron emission tomography [PET]/CT was allowed as well); 4) dental evaluation; and 5) standard hematological, liver, and renal blood studies.
Deintensified CRT
All patients were treated with IMRT. The total delivered was 60 Gy at 2 Gy per fraction for 30 fractions, 5 days a week, for 6 weeks to the high-risk regions. A dose of 54 Gy was delivered to anatomic regions at risk of subclinical disease as indicated (eg, ipsilateral and contralateral cervical and retropharyngeal lymph node basins). Unilateral RT was permitted in patients with well-lateralized tonsil primaries.
Cisplatin at a dose of 30 mg/m 2 was given intravenously weekly, preferably on Mondays. Six weekly doses were given concurrently with RT. Dose modifications were allowed as needed per the discretion of the treating medical oncologists. If a patient could not tolerate cisplatin for >1 week, they were switched to second-line agents: weekly cetuximab, carboplatin, or carboplatin/ paclitaxel.
Assessment of Response and Planned Surgical Evaluation
Four to 8 weeks after the completion of CRT, all patients were evaluated with a physical examination, fiberoptic nasolaryngopharyngoscopy, and a diagnostic CT. Response was scored separately for the primary site and the neck. A clinical complete response was defined as no measurable tumor present on physical and radiological examination and a clinical partial response was defined as a 30% reduction in long-axis measurement. Within 6 to 14 weeks after CRT, all patients underwent a surgical evaluation. If the patient had a clinical complete response at the primary site, the surgeon performed a direct visualization under anesthesia and directed biopsies of the primary site and a minimally invasive resection (transoral surgery) if the primary site demonstrated a partial response. All patients who had lymph node-positive disease at the time of presentation underwent limited/selective lymph node dissection, defined as at least the removal of all previously involved lymph node level(s) according to the classification system of the American Academy of Otolaryngology-Head and Neck Surgery. 13 If the biopsy site was pathologically positive after CRT, the surgeon was allowed to resect any suspected residual tumor with negative resection margins while maintaining organ Original Article preservation. If the neck dissection specimen was positive, additional separate neck surgery (ie, repeat neck dissection) was not performed. There was no central review of pathological specimens.
After planned surgical evaluation, patients were followed clinically every 2 to 3 months for 2 years, and then every 6 months for 3 additional years. With each clinical visit, a physical examination and indirect fiberoptic laryngoscopy were performed. Chest x-ray or chest CT was performed every 6 months for 2 years and then yearly thereafter.
Toxicity and Quality of Life Assessments
Clinician assessments of toxicity (National Cancer Institute [NCI] Common Terminology Criteria for Adverse Events [CTCAE]; version 4.03) and patient self-reported symptoms (using the patient-reported outcomes [PRO] version of the CTCAE; PRO-CTCAE), were collected before, weekly during treatment, and with every subsequent follow-up visit.
14,15 Thirty head and neck-specific items were selected from the PRO-CTCAE. 16 Patients also completed the European Organization for Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire (EORTC QLQ-C30), the EORTC QLQ-H&N35 head and neck module, and Eating Assessment Tool (EAT-10) questionnaires pretreatment, weekly during treatment, and with every subsequent follow-up visit. [17] [18] [19] The Neck Dissection Impairment Index (NDII) also was measured to assess the impact of neck dissection in the lymph node-positive patients. 20 Modified barium swallow studies were performed before CRT, 4 to 8 weeks after the completion of CRT, and 3 to 6 months after surgery. The Penetration-Aspiration Scale of Rosenbek et al was used to quantify dysphagia. 21 
Study Endpoints and Statistical Analysis
We previously reported the primary endpoint of complete pathological response rate, which was 86% and met the a priori statistical requirements. The primary endpoint of the current study was to assess the pathological complete response (pCR) rate after reduced intensity CRT in patients with HPV-associated OPSCC and compare it with the estimated rate with standard CRT of 87%, based on the reported 3-year locoregional control rate (LRC) of 87% in patients with HPV-associated OPSCC. 1 Power calculations were based on the null hypothesis that the true pCR rate is 87% and for a sample size of 40 this yields a type 1 error of 0.14. The secondary outcomes were related to tumor control and patient-reported outcomes of quality of life (QOL) and symptoms. Kaplan-Meier estimates of local control, regional control, LRC, causespecific survival, distant metastasis-free survival, and overall survival (OS) were calculated. Descriptive statistics were used to report on EORTC QLQ, PRO-CTCAE, and EAT-10 data.
RESULTS
Patient Characteristics and Compliance With Study Treatment
Patients were enrolled between February 2012 and July 2014. Study accrual was stopped once a total of 45 patients was accrued. Five patients more than the sample size calculation were accrued to account for potential loss to follow-up. One patient had a cerebrovascular accident (deemed unrelated to the study treatment or cancer) during deintensified CRT and was taken off the study, leaving 44 patients who were fully evaluable (see Supporting  Fig. 1 ). The clinical characteristics of the study population are shown in Table 1 . The majority of patients were never smokers or had 10 pack-years of tobacco use (95%). Approximately 64% were positive for HPV and p16 and 36% were negative for HPV and positive for p16. All patients received the intended RT dose of 60 Gy. Fortytwo patients (95%) received 4 weekly doses of cisplatin (70% received the planned 6 doses). The other 2 patients had platinum toxicity and received other chemotherapeutic agents (cetuximab, carboplatin). The mean overall CRT treatment time was 43 days (range, 35-50 days). There were no toxicity-related treatment delays. The median follow-up was 36 months (range, 5-53 months; 93% with 1 year and 88% with 2 years of follow-up).
Cancer Control Outcomes
The 3-year local control, regional control, LRC, causespecific survival, distant metastasis-free survival, and OS rates were 100%, 100%, 100%, 100%, and 95%, respectively. All 6 patients who achieved pathological partial responses were alive with no evidence of disease, with a median follow-up of 34 months (range, 9-48 months). Detailed information regarding these 6 patients can be found in our initial publication. 9 Five patients achieved a pCR at the primary site but pathological partial responses in the neck. One patient had <1 mm residual disease in the base of tongue and also in 1 lymph node and subsequent transoral resection of the base of tongue demonstrated no evidence of residual cancer. At the time of last follow-up, 2 patients had died (of stroke and glioblastoma, respectively). Actuarial OS is shown in Figure 1 .
Clinician-Reported Toxicity
We have previously reported the acute clinician-reported toxicity of treatment (CTCAE). 9 In summary, the incidence of acute grade 3 toxicity was 2% for xerostomia, 39% for dysphagia, and 35% for mucositis. 9 Chemotherapy-related grade 3 toxicities were minimal, at 11% for hematologic, 18% for nausea, and 5% for vomiting. 9 No patient experienced a grade 5 toxicity. Approximately 39% of patients (17 of 44 patients) required a feeding tube for a mean duration of 15 weeks (range, 5-22 weeks). None of the feeding tubes were placed prophylactically before treatment. No patient required a long-term feeding tube (0% at 1 year). We previously reported that the aspiration scores for the Penetration-Aspiration Scale of Rosenbek et al were similar pretreatment, 4 to 8 weeks after treatment, and 3 months to 6 months after surgery. All patients had minimal (ie, grade 1) long-term dysphagia and minimal to mild (ie, grade 2) xerostomia. There was no long term grade 3 toxicity.
Patient-Reported Outcomes
We previously reported the acute patient-reported symptoms of treatment (PRO-CTCAE). 9 We observed an obvious discordance in patient-reported outcomes compared with physician-reported outcomes (which is in concordance with other publications). Our observed incidence of patient-reported acute grade 3 toxicity was 75% for xerostomia, 55% for dysphagia, and 45% for mucositis. 9, 22 Figures 2 and 3 show selected domains/items from the EORTC QLQ and PRO-CTCAE. Compliance with completing the EORTC QLQ and PRO-CTCAE questionnaires at baseline, 1 year, 2 years, and 3 years was 100%, 80%, 80%, and 57%, respectively. The mean before and 3-year after EORTC QLQ scores were: global: 80 of 78 (with a lower score indicating a worse result); and swallowing: 11 of 11; dry mouth: 16 of 41; and sticky saliva: 6 of 29 (with a higher score indicating a worse result) (Fig. 2) . The mean before and 3-year after PRO-CTCAE scores (scale of 1-4, with a higher number indicating worse result) were: swallowing: 0.4 of 0.7 and dry mouth: 0.4 of 1.4 (Fig. 3) . The mean before and 3-year EAT-10 scores (on a scale of 0-40, with a higher score indicating a worse result) were 3.7 and 6.5, respectively (Fig. 4) .
DISCUSSION
The cancer control with the reduced dose CRT regimen of 60 Gy of IMRT and weekly low-dose cisplatin (30 mg/m 2 ) was excellent, with an observed 3-year causespecific survival rate of 100% and an OS rate of 95%. Our mature cancer control results are confirmatory of our preliminary pathological outcomes: the pCR rate at 9 weeks after the deintensified CRT regimen was 86% (98% for the primary site and 84% for the cervical neck lymph nodes). 9 Although 6 patients had pathological microscopic residual disease, none of these patients experienced a disease recurrence and all were alive at the time of last follow-up. We were unable to determine whether the planned surgical evaluation was therapeutic because the clonogenic viability of the residual foci cannot be determined by microscopic examination. 23 The overall severity/burden of toxicities appeared less than those of conventional CRT or transoral resection. Use of a percutaneous feeding tube is an objective measure of overall/composite treatment-related toxicity in patients with head and neck cancer. We observed a feeding tube insertion rate of 39% with a 1-year dependence rate of 0% compared with 63% and a 1-year dependence rate of 7% for conventional CRT 24 and 44% and a 1-year dependence rate of 19% for transoral surgery. 25 Patients also reported good/excellent long-term QOL and low/moderate symptom burden. Global QOL returned to baseline (Fig. 2) ; however, this should be interpreted with caution because patients may modify their conception of QOL and this may introduce measurement error (ie, response shift). 26 Long-term swallowing function was excellent, with patients reporting minimal to no worsening of their swallowing function from before treatment (Figs. 2-4) . With conventional CRT, the incidence of patient-reported grade 3 dysphagia at 1 year was approximately 9% (RTOG LENT-SOMA). 27 With deintensified CRT, patients reported their dysphagia to be on average of grade 1 at 1 year (no grade 3 as per PRO-CTCAE) (Fig. 3) . Even when the dose to the pharyngeal constrictors is reduced with conventional CRT, patients still report a worsening of swallowing function by approximately 10 points at 2 years compared with pretreatment (Head-Neck Quality of Life Questionnaire and University of Washington Head-Neck Quality of Life questionnaire). 28 In contrast, after deintensified CRT, patients reported no change in swallowing QOL at 2 years compared with pretreatment (EORTC QLQ and EAT-10) (Figs. 2 and 4) .
The greatest symptom burden appeared to be dry mouth, which patients reported to be most symptomatic at 6 to 8 weeks after deintensified CRT but it continued to improve even after 1 year. This additional recovery of function after 1 year is longer than what is observed after conventional CRT, 27, 29, 30 suggesting that in the long term the symptomatic burden/bother of dry mouth will be less with deintensified CRT.
A favorable long-term toxicity profile is expected with this deintensified regimen. The RT dose was reduced by 16% (70 to 60 Gy) and the cumulative chemotherapy dose was reduced by 40% (300 mg/m 2 to 180 mg/m 2 ). At first glance, one would think that the chemotherapy dose reduction is disproportionate to the RT dose reduction. However, the 10-Gy reduction in the RT dose is meaningful because long-term toxicity is predominately correlated to total RT dose. The dose response of normal tissue toxicity rises steeply in the high-dose range, so that modest decreases in total dose (as used in this study) can have a major impact on longterm toxicity. 31 
Limitations
The current trial was a small, single-arm phase 2 study in a favorable risk cohort of patients with OPSCC, and although we did not perform a randomized study to make a direct comparison with conventional therapy, we believe these results are very encouraging. Although our toxicity analysis is very robust with extensive physician-reported and patient-reported data, we do not have a formal comparison group with which to prove decreased toxicity.
Comparison with prior studies should be performed with caution because the current study was enriched with patients who had excellent health (majority were never smokers) and thus had a greater ability return to baseline levels of QOL. In addition, the panned surgical evaluation could be interpreted as an intensification (ie, trimodality treatment) and the possibility of the planned selective neck contributing to cancer control must be considered. We limited the surgical evaluation to a biopsy of the primary tumor site and a limited/selective neck dissection, and have previously reported that this limited surgical evaluation did not impair recovery of QOL. 32 The treatment regimen should not be considered trimodality. Definitive transoral resection of the primary tumor site and complete unilateral/bilateral neck dissections were not performed.
Future Directions and Conclusions
Going forward, the focus will be on determining the optimal deintensified regimen for patients with HPV- associated OPSCC. The major deintensified strategies are centered around: 1) transoral surgery followed by pathological risk-adapted reduced dose radiation and chemotherapy 33 ; 2) neoadjuvant chemotherapy followed by reduced dose (and possibly volume) radiation 8, 10 ; 3) substitution of traditional cytotoxic chemotherapy with targeted therapy (eg, cetuximab); 4) proton therapy 6 ; and 5) reduced dose RT and chemotherapy. 9 Each of these paradigms has their own caveats and trade-offs, with varying degrees of actual deintensification. In fact, one could argue that the net deintensification for many of these approaches is "zero." To the best of our knowledge, the approach used herein is the only one that reduces both the RT and chemotherapy dose without compensating with an increase in chemotherapy or surgical intensity. The NRG Oncology Cooperative Group has completed accrual on phase 2 randomized study (HN002) evaluating our deintensification regimen versus 60 Gy of accelerated RT alone (5 weeks at 6 fractions per week). 12 Although the results reported herein are favorable, deintensification currently remains experimental and should be performed only within the context of clinical trials with appropriate oversight, regulation, and longterm follow-up.
We continue to optimize RT and chemotherapy dose reduction in subsequent phase 2 trials. We have completed accrual (115 patients) to our second-generation phase 2 study (LCCC 1413; ClinicalTrials.gov identifier NCT02281955). At 12 weeks after deintensified CRT, only patients with PET/CT positivity undergo surgical evaluation. Other major differences in our second study included: 1) chemotherapy is omitted in patients with T0-T2, N0-N1 disease (ie, 60 Gy of IMRT alone); and 2) genomic sequencing of pretreatment biopsies is performed to be able to determine correlates of tumor response and control. Our ongoing third-generation deintensification phase 2 study (LCCC 1612; ClinicalTrials. gov NCT03077243) is investigating whether tumor genomics can be used to select patients with smoking histories of >10 pack-years in whom deintensification may be safely done. Patients with HPV-associated OPSCC regardless of smoking history are eligible (excluding those with T4 and N3 disease). Tumor genomics are performed on tumor samples of patients who have smoking histories >10 pack-years and if p53 is wild-type, they will receive deintensified CRT (60 Gy IMRT plus weekly cisplatin at a dose of 30 mg/m 2 ). If p53 is mutated, patients will receive an additional 10 Gy and another week of cisplatin at a dose of 30 mg/m 2 (70 Gy IMRT plus cumulative cisplatin at a dose of 210 mg/m 2 ). Mutations in p53 are rarely seen in patients with HPV-associated OPSCC and, when present, are indicative that tobacco may be the major driver of carcinogenesis. 34 We also are prospectively analyzing plasma-circulating HPV tumor DNA to evaluate its predictive and prognostic value.
The long-term cancer control and patient-reported outcomes are excellent with a deintensified CRT regimen of 60 Gy IMRT with concurrent weekly low-dose cisplatin (30 mg/m 2 ) for patients with favorable risk HPVassociated OPSCC. Further efforts are warranted to optimize reductions in treatment intensity.
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